Abstract
Background: Up to date, there have been some studies indicating positive effects of stem cells on treating the liver cirrhosis. In this study, we compared the effectiveness of two methods in which mesenchymal stem cells harvested from umbilical cord blood (UCB-MSCs) were transfused either via portal or tail veins to the mouse models of liver cirrhosis.
 Methods: Liver cirrhosis was induced by CCl4 (1 ml/kg) on male Swiss mice within 11 weeks, followed by administration of 106 UCB-MSCs via the portal or tail vein. After 21 days, blood samples were collected for measuring transaminase, bilirubin and albumin activities. The expression of fibrosis-associated genes, specifically procollagen – alpha 1 and integrin – beta1, were assessed using qRT-PCR. The histopathology was also evaluated using hematoxylin/eosin, Masson trichrome staining and immunohistochemistry with collagen type 1 and alpha-SMA antibody.
 Results: UCB-MSCs transplantation significantly improved post-21 days of treatment in the liver fibrosis mice as compared with placebo group. Notably, UCB-MSCs transferred through portal veins revealed a more positive effect than via tail veins as indicated by the improvement in the biochemical indexes, fibrosis-related genes expression, and liver histopathology.
 Conclusion: The UCB-MSCs therapy proved to be a promising method for treating the liver cirrhosis. The method of delivering stem cells through portal vein was more effective than through tail vein
Highlights
Up to date, there have been some studies indicating positive effects of stem cells on treating the liver cirrhosis
We compared the effectiveness of two methods in which mesenchymal stem cells harvested from umbilical cord blood (UCB-MSCs) were transfused either via portal or tail veins to the mouse models of liver cirrhosis
Liver cirrhosis was induced by CCl4 (1 ml/kg) on male Swiss mice within 11 weeks, followed by administration of 106 UCB-MSCs via the portal or tail vein
Summary
Background: Up to date, there have been some studies indicating positive effects of stem cells on treating the liver cirrhosis. We compared the effectiveness of two methods in which mesenchymal stem cells harvested from umbilical cord blood (UCB-MSCs) were transfused either via portal or tail veins to the mouse models of liver cirrhosis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
